Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835671 | 0.92 | LMNA (0.39) | PARP14LMNATP53POLBMAPT | |
| SCHEMBL6834504 | 0.92 | LMNA (0.47) | PARP14LMNARXFP1ALBPKM | |
| SCHEMBL6833821 | 0.90 | NHERF1 (0.43) | PARP14KCNQ2LMNAPOLBALB | |
| SCHEMBL6833157 | 0.90 | PARP14 (0.42) | PARP14KCNQ2LMNAPOLBALB | |
| SCHEMBL6830257 | 0.89 | RXFP1 (0.48) | PARP14KCNQ2MAPTRXFP1 | |
| SCHEMBL6834298 | 0.89 | MEN1 (0.44) | PARP14LMNAPKM | |
| SCHEMBL6833069 | 0.88 | POLB (0.48) | PARP14KCNQ2LMNATP53POLB | |
| SCHEMBL6833337 | 0.87 | RXFP1 (0.45) | PARP14LMNARXFP1ALBHDAC2 | |
| SCHEMBL6818890 | 0.87 | TRPV1 (0.46) | PARP14KCNQ2LMNAMAPTALB | |
| SCHEMBL6834072 | 0.87 | ALDH1A1 (0.41) | PARP14LMNAMAPTALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PARP14 2395/4885KCNQ2 2555/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.